


Brief Biography

| | | |
|--------------|--------------------------|--|
| Name | Jae-ho, Yoon, MD |  |
| Major | Department of Hematology | |

| | |
|------------------------|--|
| Education | 1997.3 – 2003.2 Bachelor's degree The Catholic university of Korea, Seoul, Korea 2010.3 – 2014.2 Degree of master of internal medicine The Catholic Univ. of Korea, graduate school, in school |
| Position | 2003.03 – 2008.02 Internship plus resident, Department of Internal Medicine, Catholic medical center, The Catholic Univ. of Korea 2008.05 – 2011.04 Medical doctor, Department of Internal medicine Go-seong public health institute of Kangwon-do, Korea 2011.05 – 2018.02 Clinical Fellowship and assistant professor, 2018.03 – 2020.02 Assistant professor, Department of Hematology, Catholic Hematology Hospital, Korea 2020.03 - Present Associate professor, Department of Hematology, Catholic Hematology Hospital, Korea |
| Awards | 2012 Best abstract of KJH. The 53 rd Congress of the Korean Society of Hematology 2013 Award for the best abstract, The 18 th Congress of the Korean Society of BMT 2015 Award for the best research paper, The Korean Journal of Internal Medicine. 2017 Award for the best young investigator, Korean Society of Hematology 2018 Award for the best young investigator, Korean Society of BMT 2020 Award for the best young investigator, Korean Society of Hematology |
| Activity | Korean Society of Hematology Korean Society of Hematopoietic Stem Cell Transplantation Korean Society of Internal Medicine American Society of Hematology |
| Research papers | Lee SH, Yoon JH (Co-first author) , Min GJ, Park SS, Park S, Lee SE, et al. Response to blinatumomab or inotuzumab ozogamicin for isolated extramedullary relapse of adult acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation: a case study. Int J Hematol. 2022;115(1):135-9. Lee S, Yoon JH (Correspondence) , Lee E, Park SS, Park MS, Jung J, Min GJ, et al. Prediction and recommendation by machine learning through repetitive internal validation for hepatic veno-occlusive disease/sinusoidal obstruction syndrome and early death after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2022. Kwag D, Yoon JH (Correspondence) , Min GJ, Park SS, Park S, Lee SE, et al. Splenectomy Outcomes in Relapsed or Refractory Immune Thrombocytopenia According to First-Line Intravenous Immunoglobulin Response. Acta Haematol. 2022. Lee J, Yoon JH (Co-first author) , Kwag D, Lee JH, Kim TY, Min GJ, et al. Hepatic venoocclusive disease/sinusoidal obstruction syndrome with normal portal vein flow mimicking aggravated chronic hepatic GVHD following inotuzumab ozogamicin salvage therapy: a case report of pathologic-radiologic discrepancy. Therapeutic advances in hematology. 2021;12:20406207211066176. Cho H, Kim Y, Yoon JH (Co-first author) , Lee J, Lee GD, Son J, et al. Non-inferior long-term outcomes of adults with Philadelphia chromosome-like acute lymphoblastic leukemia. Bone Marrow Transplant. 2021. Yoon JH , Choi CW, Won JH. Hepatic sinusoidal obstruction syndrome/veno-occlusive disease after hematopoietic cell transplantation: historical and current considerations in Korea. The Korean journal of |

internal medicine. 2021.

Oh EJ, **Yoon JH (Correspondence)**, Park KH, Bae HJ, Yun SJ, Min GJ, et al. Natural-killer cell cytotoxicity as a diagnostic and prognostic marker for adult patients with secondary hemophagocytic lymphohistiocytosis: a prospective phase II observational study. *Therapeutic advances in hematology*. 2021;12:20406207211020544.

Yoon JH, Min GJ, Park SS, Park S, Lee SE, Cho BS *et al.* Incidence and risk factors of hepatic veno-occlusive disease/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation in adults with prophylactic ursodiol and intravenous heparin or prostaglandin E1. *Bone Marrow Transplant* 2021. e-pub ahead of print 2021/02/03; doi: 10.1038/s41409-021-01215-y

Yoon JH, Min GJ, Park SS, Park S, Lee SE, Cho BS *et al.* Impact of donor type on long-term graft-versus-host disease-free/relapse-free survival for adult acute lymphoblastic leukemia in first remission. *Bone Marrow Transplant* 2021; **56**(4): 828-840. e-pub ahead of print 2020/11/01; doi: 10.1038/s41409-020-01097-6

Cho H, Kim Y, **Yoon JH (Co-first author)**, Lee J, Lee GD, Son J *et al.* Non-inferior long-term outcomes of adults with Philadelphia chromosome-like acute lymphoblastic leukemia. *Bone Marrow Transplant* 2021. e-pub ahead of print 2021/04/08; doi: 10.1038/s41409-021-01253-6

Yoon JH, Park SS, Min GJ, Park S, Lee SE, Cho BS *et al.* Experiences of allogeneic hematopoietic cell transplantation following non-myeloablative conditioning regimen in severely comorbid patients with myelofibrosis: case series with a patient presenting with extensive extramedullary hematopoiesis. *Therapeutic advances in hematology* 2020; **11**: 2040620720932038. e-pub ahead of print 2020/07/14

Yoon JH, Min GJ, Park SS, Park S, Lee SE, Cho BS *et al.* HLA-mismatched donor and high ferritin level showed poor clinical outcomes after allogeneic hematopoietic cell transplantation in patients with advanced myelofibrosis. *Therapeutic advances in hematology* 2020; **11**: 2040620720936935. e-pub ahead of print 2020/10/01

Yoon SY, **Yoon JH (Co-first author)**, Min GJ, Park SS, Park S, Lee SE *et al.* Experience of blinatumomab salvage for patients with acute lymphoblastic leukemia presenting with isolated extramedullary relapse after previous allogeneic hematopoietic cell transplantation. *Bone Marrow Transplant* 2020; **55**(7): 1469-1472

Yoon JH, Min GJ, Park SS, Park S, Lee SE, Cho BS *et al.* Impact of donor type on long-term graft-versus-host disease-free/relapse-free survival for adult acute lymphoblastic leukemia in first remission. *Bone Marrow Transplant* 2020. e-pub ahead of print

Yoon JH, Min GJ, Park SS, Park S, Lee SE, Cho BS *et al.* Feasible outcome of blinatumomab followed by allogeneic hematopoietic cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. *Cancer medicine* 2019. doi: 10.1002/cam4.2680

Yoon JH, Kim HJ, Min GJ, Park SS, Jeon YW, Lee SE, et al. Progressive hyperleukocytosis is a relevant predictive marker for differentiation syndrome, early death, and subsequent relapse in acute promyelocytic leukemia. *Scientific reports*. 2019;9(1):11935.

Yoon JH, Min GJ, Park SS, Jeon YW, Lee SE, Cho BS, et al. Minimal residual disease-based long-term efficacy of reduced-intensity conditioning versus myeloablative conditioning for adult Philadelphia-positive acute lymphoblastic leukemia. *Cancer*. 2019;125(6):873-83.

Yoon JH, Min GJ, Park SS, Jeon YW, Lee SE, Cho BS, et al. Autologous hematopoietic cell transplantation using dose-reduced intravenous busulfan, melphalan, and thiotepa for high-risk or relapsed lymphomas. *Bone Marrow Transplant*. 2019;54(2):330-3.

Yoon JH, Park SS, Jeon YW, Lee SE, Cho BS, Eom KS, et al. Treatment outcomes and prognostic factors in adult patients with secondary hemophagocytic lymphohistiocytosis not associated with malignancy. *Haematologica*. 2019;104(2):269-76.

Yoon JH, Yoo KH, Sung KW, Jung CW, Kim JS, Hahn SM, et al. Validation of treatment outcomes according to revised severity criteria from European Society for Blood and Marrow Transplantation (EBMT) for sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD). *Bone Marrow Transplant*. 2019;54(8):1361-8.

Yoon JH et al. The effects of early intensified induction chemotherapy in adult patients with acute myeloid leukemia compared to standard 3+7 chemotherapy. *Blood res* 2017;52(3):174-83.

Yoon JH, Kim HJ, Park SS, Jeon YW, Lee SE, Cho BS, et al. Clinical Outcome of Autologous Hematopoietic Cell Transplantation in Adult Patients with Acute Myeloid Leukemia: Who May Benefit from Autologous Hematopoietic Cell Transplantation? *Biol Blood Marrow Transplant*. 2017;23(4):588-97.

Yoon JH, Kim HJ, Park SS, Jeon YW, Lee SE, Cho BS, et al. Long-term clinical outcomes of hematopoietic cell transplantation for intermediate-to-poor-risk acute myeloid leukemia during first remission according to available donor types. *Oncotarget*. 2017;8(25):38-45.

Yoon JH, Kim HJ, Kwak DH, Park SS, Jeon YW, Lee SE, et al. High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: a single-center cohort study. *J Hematol Oncol*. 2017;10(1):30.

Yoon JH, Jeon YW, Lee SE, Cho BS, Eom KS, Kim YJ, et al. Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.

Hematol Oncol. 2017;35(1):17-24.

Yoon JH, Yhim HY, Kwak JY, Ahn JS, Yang DH, Lee JJ, et al. Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia. *Ann Oncol*. 2016;27(6):1081-8.

Yoon JH, Lee S, Kim HJ, Jeon YW, Lee SE, Cho BS, et al. Impact of cytomegalovirus reactivation on relapse and survival in patients with acute leukemia who received allogeneic hematopoietic stem cell transplantation in first remission. *Oncotarget*. 2016;7(13):17230-41.

Yoon JH et al. Role of the frontline autologous stem cell transplantation for high-risk young DLBCL patients who showed sensitivity to R-CHOP: Retrospective comparative analysis with a well-matched risk group treated with R-CHOP alone. *Korean J Intern Med*. 2015;30(3):362-71.

Yoon JH, Kim HJ, Jeon YW, Lee SE, Cho BS, Eom KS, et al. Outcome of allogeneic hematopoietic stem cell transplantation for cytogenetically normal AML and identification of high-risk subgroup using WT1 expression in association with NPM1 and FLT3-ITD mutations. *Genes Chromosomes Cancer*. 2015;54(8):489-99.

Yoon JH, Jeon YW, Yahng SA, Shin SH, Lee SE, Cho BS, et al. Wilms Tumor Gene 1 Expression as a Predictive Marker for Relapse and Survival after Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes. *Biol Blood Marrow Transplant*. 2015;21(3):460-7.

Yoon JH, Kim HJ, Kim JW, Jeon YW, Shin SH, Lee SE, et al. Identification of molecular and cytogenetic risk factors for unfavorable core-binding factor-positive adult AML with post-remission treatment outcome analysis including transplantation. *Bone Marrow Transplant*. 2014;49(12):1466-74.

Yoon JH, Lee S, Kim HJ, Lee JW, Min WS, Chung BH, Yang CW, Kim YS, Kim JI, Moon IS, Oh EJ, Park GS, Cho SG. Comparative analysis of post-transplant lymphoproliferative disorder after kidney transplantation versus hematopoietic stem cell transplantation. *Transplant international : official journal of the European Society for Organ Transplantation*. 2014;27(7):721-32.

Yoon JH, Kim HJ, Shin SH, Lee SE, Cho BS, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Park CW. Stratification of de novo adult AML with adverse-risk karyotype: Can we overcome the worse prognosis of adverse-risk group AML with hematopoietic stem cell transplantation? *Biol Blood Marrow Transplant* 2014;20(1):80-8.

Yoon JH, Kim Y, Yahng SA, Shin SH, Lee SE, Cho BS, Eom KS, Kim YJ, Lee S, Kim HJ, Min CK, Kim DW, Lee JW, Min WS, Park CW, Lim J, Han K, Kim M, Cho SG. Validation of Western common recurrent chromosomal aberrations in Korean chronic lymphocytic leukaemia patients with very low incidence. *Hematol Oncol* 2014;32(4):169-77.

Yoon JH, Cho BS, Kim HJ, Kim JH, Shin SH, Yahng SA, et al. Outcomes of elderly de novo acute myeloid leukemia treated by a risk-adapted approach based on age, comorbidity, and performance status. *Am J Hematol*. 2013;88(12):1074-81.

Yoon JH, Min WS, Kim HJ, Kim JH, Shin SH, Yahng SA, Lee SE, Cho BS, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Park CW. Experiences of t-PA use in moderate-to-severe hepatic veno-occlusive disease after hematopoietic SCT: is it still reasonable to use t-PA? *Bone Marrow Transplant* 2013.

Yoon JH, Kim HJ, Shin SH, Yahng SA, Lee SE, Cho BS, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Min WS, Park CW, Lim JH. Implication of higher BAALC expression in combination with other gene mutations in adult cytogenetically normal acute myeloid leukemia. *Leuk Lymphoma* 2013.

Yoon JH, Kim HJ, Shin SH, Yahng SA, Lee SE, Cho BS, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Min WS, Park CW, Lim JH. Serial measurement of WT1 expression and decrement ratio until hematopoietic cell transplantation as a marker of residual disease in patients with cytogenetically normal acute myelogenous leukemia. *Biol Blood Marrow Transplant* 2013;19:958-966.

Yoon JH, Kim HJ, Shin SH, Yahng SA, Lee SE, Cho BS, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Min WS, Park CW, Lim JH. BAALC and WT1 expressions from diagnosis to hematopoietic stem cell transplantation: consecutive monitoring in adult patients with core-binding-factor-positive AML. *Eur J Haematol* 2013;91:112-121.

Yoon JH, Kim HJ, Shin SH, Yahng SA, Cho BS, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Min WS, Park CW. Normal karyotype mosaicism in adult AML patients with adverse-risk and undefined karyotype: preliminary report of treatment outcomes after hematopoietic stem cell transplantation. *Int J Hematol* 2013;97:773-781.